Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer

被引：356

作者：

Halabi, Susan ^{[1
]}

Kelly, William Kevin ^{[2
]}

Ma, Hua ^{[1
]}

Zhou, Haojin ^{[3
]}

Solomon, Nicole C. ^{[1
]}

Fizazi, Karim ^{[4
]}

Tangen, Catherine M. ^{[5
]}

Rosenthal, Mark ^{[6
]}

Petrylak, Daniel P. ^{[7
]}

Hussain, Maha ^{[8
]}

Vogelzang, Nicholas J. ^{[9
]}

Thompson, Ian M. ^{[10
]}

Chi, Kim N. ^{[12
]}

de Bono, Johann ^{[14
]}

Armstrong, Andrew J. ^{[1
]}

Eisenberger, Mario A. ^{[15
]}

Fandi, Abderrahim ^{[16
]}

Li, Shaoyi ^{[16
]}

Araujo, John C. ^{[11
]}

Logothetis, Christopher J. ^{[11
]}

Quinn, David I. ^{[17
]}

Morris, Michael J. ^{[20
]}

Higano, Celestia S. ^{[19
]}

Tannock, Ian F. ^{[13
]}

Small, Eric J. ^{[18
]}

机构：

[1] Duke Univ, 2424 Erwin Rd,Ste 11088, Durham, NC 27710 USA

[2] Thomas Jefferson Univ, Sidney Kimmel Med Coll, Philadelphia, PA 19107 USA

[3] Merck, Beijing, Peoples R China

[4] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France

[5] Southwest Oncol Grp Stat Ctr, Seattle, WA USA

[6] Royal Melbourne Hosp, Melbourne, Vic, Australia

[7] Yale Canc Ctr, New Haven, CT USA

[8] Univ Michigan, Ann Arbor, MI 48109 USA

[9] US Oncol, Las Vegas, NV USA

[10] Univ Texas San Antonio, San Antonio, TX USA

[11] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[12] British Columbia Canc Agcy, Vancouver Canc Ctr, Vancouver, BC V5Z 4E6, Canada

[13] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[14] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England

[15] Johns Hopkins Univ, Sch Med, Ctr Oncol, Baltimore, MD 21205 USA

[16] Celgene Corp, Summit, NJ USA

[17] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA

[18] Univ Calif San Francisco, San Francisco, CA 94143 USA

[19] Univ Washington, Seattle, WA 98195 USA

[20] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 14期

基金：

美国国家卫生研究院;

关键词：

DOCETAXEL PLUS PREDNISONE; PHASE-III TRIAL; DOUBLE-BLIND; PROGNOSTIC MODEL; PLACEBO; CHEMOTHERAPY; MITOXANTRONE; COMBINATION;

D O I：

10.1200/JCO.2015.65.7270

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose Reports have suggested that metastatic site is an important predictor of overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC), but these were based on a limited number of patients. We investigate the impact of site of metastases on OS of a substantial sample of men with mCRPC who received docetaxel chemotherapy in nine phase III trials. Patients and Methods Individual patient data from 8,820 men with mCRPC enrolled onto nine phase III trials were combined. Site of metastases was categorized as lymph node (LN) only, bone with or without LN (with no visceral metastases), any lung metastases (but no liver), and any liver metastases. Results Most patients had bone with or without LN metastases (72.8%), followed by visceral disease (20.8%) and LN-only disease (6.4%). Men with liver metastases had the worst median OS (13.5 months). Although men with lung metastases had better median OS (19.4 months) compared with menwith liver metastases, they had significantly worse median survival duration than men with nonvisceral bone metastases (21.3 months). Men with LN-only disease had a median OS of 31.6 months. The pooled hazard ratios for death in men with lung metastases compared with men with bone with or without LN metastases and in men with any liver metastases compared with men with lung metastases were 1.14 (95% CI, 1.04 to 1.25; P = .007) and 1.52 (95% CI, 1.35 to 1.73; P < .0001), respectively. Conclusion Specific sites of metastases in men with mCRPC are associated with differential OS, with successive increased lethality for lung and liver metastases compared with bone and nonvisceral involvement. These data may help in treatment decisions, the design of future clinical trials, and understanding the variation in biology of different sites of metastases in men with mCRPC. (C) 2016 by American Society of Clinical Oncology

引用

页码：1652 / U191

页数：13

共 28 条

[1]

[Anonymous], J CLIN ONCOL S

[2] Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial [J].

Araujo, John C. ;

Trudel, Geralyn C. ;

Saad, Fred ;

Armstrong, Andrew J. ;

Yu, Evan Y. ;

Bellmunt, Joaquim ;

Wilding, George ;

McCaffrey, John ;

Serrano, Sergio V. ;

Matveev, Vsevolod B. ;

Efstathiou, Eleni ;

Oudard, Stephane ;

Morris, Michael J. ;

Sizer, Bruce ;

Goebell, Peter J. ;

Heidenreich, Axel ;

de Bono, Johann S. ;

Begbie, Stephen ;

Hong, Jun H. ;

Richardet, Eduardo ;

Gallardo, Enrique ;

Paliwal, Prashni ;

Durham, Susan ;

Cheng, Shinta ;

Logothetis, Christopher J. .

LANCET ONCOLOGY, 2013, 14 (13) :1307-1316

[3] A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis [J].

Armstrong, Andrew J. ;

Garrett-Mayer, Elizabeth S. ;

Yang, Yi-Chun Ou ;

de Wit, Ronald ;

Tannock, Ian F. ;

Eisenberger, Mario .

CLINICAL CANCER RESEARCH, 2007, 13 (21) :6396-6403

[4]

Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095

[5]

Chi KN, 2015, J CLIN ONCOL S, V33

[6] METAANALYSIS IN CLINICAL-TRIALS [J].

DERSIMONIAN, R ;

LAIRD, N .

CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188

[7] Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 [J].

Fizazi, Karim ;

Jones, Robert ;

Oudard, Stephane ;

Efstathiou, Eleni ;

Saad, Fred ;

de Wit, Ronald ;

De Bono, Johann ;

Cruz, Felipe Melo ;

Fountzilas, George ;

Ulys, Albertas ;

Carcano, Flavio ;

Agarwal, Neeraj ;

Agus, David ;

Bellmunt, Joaquim ;

Petrylak, Daniel P. ;

Lee, Shih-Yuan ;

Webb, Iain J. ;

Tejura, Bindu ;

Borgstein, Niels ;

Dreicer, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07) :723-731

[8]

Fizazi K, 2013, J CLIN ONCOL, V31

[9] Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer [J].

Fizazi, Karim S. ;

Higano, Celestia S. ;

Nelson, Joel B. ;

Gleave, Martin ;

Miller, Kurt ;

Morris, Thomas ;

Nathan, Faith E. ;

McIntosh, Stuart ;

Pemberton, Kristine ;

Moul, Judd W. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (14) :1740-+

[10] Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer [J].

Halabi, S ;

Small, EJ ;

Kantoff, PW ;

Kattan, MW ;

Kaplan, EB ;

Dawson, NA ;

Levine, EG ;

Blumenstein, BA ;

Vogelzang, NJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (07) :1232-1237

← 1 2 3 →